SV BR 1 GM cancer vaccine ( BriaCell Therapeutics)
- Generic Name
- SV BR 1 GM cancer vaccine ( BriaCell Therapeutics)
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Phase 3
Recruiting
- Conditions
- Metastatic Breast CancerBreast NeoplasmEnd Stage CancerBreast CancerBreast Cancer Metastatic
- Interventions
- Drug: Treatment of Physician's ChoiceDrug: Interferon infiltration of the inoculation site
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- BriaCell Therapeutics Corporation
- Target Recruit Count
- 404
- Registration Number
- NCT06072612
- Locations
- 🇺🇸
Los Angeles cancer Network_Anaheim, Anaheim, California, United States
🇺🇸Los Angeles Cancer Network_Corona, Corona, California, United States
🇺🇸Los Angeles cancer Network_Fountain Vallley, Fountain Valley, California, United States
Combination Study of SV-BR-1-GM With Retifanlimab
Phase 1
- Conditions
- Breast CancerBreast Cancer MetastaticBreast NeoplasmMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- BriaCell Therapeutics Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT03328026
- Locations
- 🇺🇸
Nebraska Cancer Specialists, Omaha, Nebraska, United States
🇺🇸St. Joseph Heritage Healthcare, Santa Rosa, California, United States
🇺🇸St Vincent-Frontier Cancer Center, Billings, Montana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath